Loading
A phase 2 trial of Fulvestrant and TQB3616 in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., active and no longer recruiting.
Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer is a phase 2 interventional study registered as NCT06702618 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 33 participants enrolled, started 2025-02-20 and due to reach its primary completion in 2026-06. Interventions recorded: TQB3616 capsule+Fulvestrant Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TQB3616, Sino Biopharmaceutical (Chia Tai Tianqing), Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/